nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP3A5—Gefitinib—lung cancer	0.037	0.0613	CbGbCtD
Aprepitant—CYP3A5—Teniposide—lung cancer	0.0359	0.0595	CbGbCtD
Aprepitant—CYP2C19—Gefitinib—lung cancer	0.0299	0.0495	CbGbCtD
Aprepitant—CYP2C19—Teniposide—lung cancer	0.029	0.048	CbGbCtD
Aprepitant—CYP3A7—Paclitaxel—lung cancer	0.0267	0.0443	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Paclitaxel—lung cancer	0.0267	0.0443	CbGbCtD
Aprepitant—CYP3A7—Irinotecan—lung cancer	0.0264	0.0437	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Irinotecan—lung cancer	0.0264	0.0437	CbGbCtD
Aprepitant—CYP2C9—Gefitinib—lung cancer	0.0248	0.0411	CbGbCtD
Aprepitant—CYP2C9—Teniposide—lung cancer	0.0241	0.0399	CbGbCtD
Aprepitant—CYP3A5—Crizotinib—lung cancer	0.0227	0.0376	CbGbCtD
Aprepitant—CYP3A5—Erlotinib—lung cancer	0.0219	0.0363	CbGbCtD
Aprepitant—CYP3A5—Paclitaxel—lung cancer	0.02	0.0332	CbGbCtD
Aprepitant—CYP3A5—Irinotecan—lung cancer	0.0198	0.0328	CbGbCtD
Aprepitant—CYP3A7-CYP3A51P—Docetaxel—lung cancer	0.0193	0.032	CbGbCtD
Aprepitant—CYP3A7—Docetaxel—lung cancer	0.0193	0.032	CbGbCtD
Aprepitant—CYP1A2—Erlotinib—lung cancer	0.0163	0.027	CbGbCtD
Aprepitant—CYP3A5—Etoposide—lung cancer	0.0158	0.0262	CbGbCtD
Aprepitant—CYP3A4—Topotecan—lung cancer	0.0158	0.0262	CbGbCtD
Aprepitant—CYP3A5—Docetaxel—lung cancer	0.0145	0.024	CbGbCtD
Aprepitant—CYP3A4—Gefitinib—lung cancer	0.0144	0.0239	CbGbCtD
Aprepitant—CYP3A4—Teniposide—lung cancer	0.014	0.0232	CbGbCtD
Aprepitant—CYP2C9—Paclitaxel—lung cancer	0.0134	0.0223	CbGbCtD
Aprepitant—CYP1A2—Etoposide—lung cancer	0.0118	0.0195	CbGbCtD
Aprepitant—CYP3A4—Vinorelbine—lung cancer	0.0111	0.0184	CbGbCtD
Aprepitant—CYP2C9—Cisplatin—lung cancer	0.0108	0.0179	CbGbCtD
Aprepitant—CYP3A4—Crizotinib—lung cancer	0.00885	0.0147	CbGbCtD
Aprepitant—CYP3A4—Erlotinib—lung cancer	0.00854	0.0141	CbGbCtD
Aprepitant—CYP3A4—Paclitaxel—lung cancer	0.00781	0.0129	CbGbCtD
Aprepitant—CYP3A4—Irinotecan—lung cancer	0.00771	0.0128	CbGbCtD
Aprepitant—CYP3A4—Vinblastine—lung cancer	0.00685	0.0114	CbGbCtD
Aprepitant—CYP3A4—Etoposide—lung cancer	0.00617	0.0102	CbGbCtD
Aprepitant—CYP3A4—Docetaxel—lung cancer	0.00565	0.00936	CbGbCtD
Aprepitant—CYP3A4—Doxorubicin—lung cancer	0.00421	0.00698	CbGbCtD
Aprepitant—Dysuria—Doxorubicin—lung cancer	7.4e-05	0.00027	CcSEcCtD
Aprepitant—Neutropenia—Doxorubicin—lung cancer	7.4e-05	0.00027	CcSEcCtD
Aprepitant—Decreased appetite—Paclitaxel—lung cancer	7.39e-05	0.00027	CcSEcCtD
Aprepitant—Dry mouth—Docetaxel—lung cancer	7.36e-05	0.000268	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Doxorubicin—lung cancer	7.35e-05	0.000268	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Paclitaxel—lung cancer	7.34e-05	0.000268	CcSEcCtD
Aprepitant—Fatigue—Paclitaxel—lung cancer	7.33e-05	0.000267	CcSEcCtD
Aprepitant—Pollakiuria—Doxorubicin—lung cancer	7.31e-05	0.000267	CcSEcCtD
Aprepitant—Asthenia—Gemcitabine—lung cancer	7.29e-05	0.000266	CcSEcCtD
Aprepitant—Constipation—Paclitaxel—lung cancer	7.27e-05	0.000265	CcSEcCtD
Aprepitant—Pain—Paclitaxel—lung cancer	7.27e-05	0.000265	CcSEcCtD
Aprepitant—Confusional state—Docetaxel—lung cancer	7.27e-05	0.000265	CcSEcCtD
Aprepitant—Pharyngitis—Methotrexate—lung cancer	7.26e-05	0.000265	CcSEcCtD
Aprepitant—Urinary tract disorder—Methotrexate—lung cancer	7.22e-05	0.000263	CcSEcCtD
Aprepitant—Photosensitivity reaction—Doxorubicin—lung cancer	7.22e-05	0.000263	CcSEcCtD
Aprepitant—Anaphylactic shock—Docetaxel—lung cancer	7.21e-05	0.000263	CcSEcCtD
Aprepitant—Oedema—Docetaxel—lung cancer	7.21e-05	0.000263	CcSEcCtD
Aprepitant—Weight increased—Doxorubicin—lung cancer	7.2e-05	0.000263	CcSEcCtD
Aprepitant—Pruritus—Gemcitabine—lung cancer	7.19e-05	0.000262	CcSEcCtD
Aprepitant—Urethral disorder—Methotrexate—lung cancer	7.17e-05	0.000261	CcSEcCtD
Aprepitant—Infection—Docetaxel—lung cancer	7.16e-05	0.000261	CcSEcCtD
Aprepitant—Weight decreased—Doxorubicin—lung cancer	7.16e-05	0.000261	CcSEcCtD
Aprepitant—Feeling abnormal—Etoposide—lung cancer	7.15e-05	0.000261	CcSEcCtD
Aprepitant—Hyperglycaemia—Doxorubicin—lung cancer	7.14e-05	0.00026	CcSEcCtD
Aprepitant—Diarrhoea—Irinotecan—lung cancer	7.14e-05	0.00026	CcSEcCtD
Aprepitant—Pneumonia—Doxorubicin—lung cancer	7.1e-05	0.000259	CcSEcCtD
Aprepitant—Gastrointestinal pain—Etoposide—lung cancer	7.09e-05	0.000259	CcSEcCtD
Aprepitant—Shock—Docetaxel—lung cancer	7.09e-05	0.000259	CcSEcCtD
Aprepitant—Nervous system disorder—Docetaxel—lung cancer	7.07e-05	0.000258	CcSEcCtD
Aprepitant—Thrombocytopenia—Docetaxel—lung cancer	7.06e-05	0.000257	CcSEcCtD
Aprepitant—Infestation NOS—Doxorubicin—lung cancer	7.05e-05	0.000257	CcSEcCtD
Aprepitant—Infestation—Doxorubicin—lung cancer	7.05e-05	0.000257	CcSEcCtD
Aprepitant—Tachycardia—Docetaxel—lung cancer	7.04e-05	0.000257	CcSEcCtD
Aprepitant—Feeling abnormal—Paclitaxel—lung cancer	7.01e-05	0.000256	CcSEcCtD
Aprepitant—Skin disorder—Docetaxel—lung cancer	7e-05	0.000255	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Doxorubicin—lung cancer	6.99e-05	0.000255	CcSEcCtD
Aprepitant—Hypersensitivity—Cisplatin—lung cancer	6.98e-05	0.000254	CcSEcCtD
Aprepitant—Gastrointestinal pain—Paclitaxel—lung cancer	6.96e-05	0.000254	CcSEcCtD
Aprepitant—Diarrhoea—Gemcitabine—lung cancer	6.95e-05	0.000254	CcSEcCtD
Aprepitant—Renal failure—Doxorubicin—lung cancer	6.93e-05	0.000253	CcSEcCtD
Aprepitant—Erythema multiforme—Methotrexate—lung cancer	6.92e-05	0.000252	CcSEcCtD
Aprepitant—Neuropathy peripheral—Doxorubicin—lung cancer	6.92e-05	0.000252	CcSEcCtD
Aprepitant—Dizziness—Irinotecan—lung cancer	6.9e-05	0.000252	CcSEcCtD
Aprepitant—Urticaria—Etoposide—lung cancer	6.89e-05	0.000251	CcSEcCtD
Aprepitant—Stomatitis—Doxorubicin—lung cancer	6.88e-05	0.000251	CcSEcCtD
Aprepitant—Anorexia—Docetaxel—lung cancer	6.87e-05	0.000251	CcSEcCtD
Aprepitant—Body temperature increased—Etoposide—lung cancer	6.86e-05	0.00025	CcSEcCtD
Aprepitant—Abdominal pain—Etoposide—lung cancer	6.86e-05	0.00025	CcSEcCtD
Aprepitant—Conjunctivitis—Doxorubicin—lung cancer	6.86e-05	0.00025	CcSEcCtD
Aprepitant—Urinary tract infection—Doxorubicin—lung cancer	6.86e-05	0.00025	CcSEcCtD
Aprepitant—Eye disorder—Methotrexate—lung cancer	6.84e-05	0.000249	CcSEcCtD
Aprepitant—Tinnitus—Methotrexate—lung cancer	6.82e-05	0.000249	CcSEcCtD
Aprepitant—Asthenia—Cisplatin—lung cancer	6.79e-05	0.000248	CcSEcCtD
Aprepitant—Cardiac disorder—Methotrexate—lung cancer	6.79e-05	0.000248	CcSEcCtD
Aprepitant—Urticaria—Paclitaxel—lung cancer	6.76e-05	0.000246	CcSEcCtD
Aprepitant—Hypotension—Docetaxel—lung cancer	6.74e-05	0.000246	CcSEcCtD
Aprepitant—Haematuria—Doxorubicin—lung cancer	6.73e-05	0.000245	CcSEcCtD
Aprepitant—Abdominal pain—Paclitaxel—lung cancer	6.72e-05	0.000245	CcSEcCtD
Aprepitant—Body temperature increased—Paclitaxel—lung cancer	6.72e-05	0.000245	CcSEcCtD
Aprepitant—Angiopathy—Methotrexate—lung cancer	6.64e-05	0.000242	CcSEcCtD
Aprepitant—Vomiting—Irinotecan—lung cancer	6.63e-05	0.000242	CcSEcCtD
Aprepitant—Immune system disorder—Methotrexate—lung cancer	6.61e-05	0.000241	CcSEcCtD
Aprepitant—Mediastinal disorder—Methotrexate—lung cancer	6.59e-05	0.00024	CcSEcCtD
Aprepitant—Rash—Irinotecan—lung cancer	6.58e-05	0.00024	CcSEcCtD
Aprepitant—Dermatitis—Irinotecan—lung cancer	6.57e-05	0.00024	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Docetaxel—lung cancer	6.57e-05	0.00024	CcSEcCtD
Aprepitant—Chills—Methotrexate—lung cancer	6.56e-05	0.000239	CcSEcCtD
Aprepitant—Headache—Irinotecan—lung cancer	6.53e-05	0.000238	CcSEcCtD
Aprepitant—Insomnia—Docetaxel—lung cancer	6.52e-05	0.000238	CcSEcCtD
Aprepitant—Diarrhoea—Cisplatin—lung cancer	6.48e-05	0.000236	CcSEcCtD
Aprepitant—Paraesthesia—Docetaxel—lung cancer	6.47e-05	0.000236	CcSEcCtD
Aprepitant—Alopecia—Methotrexate—lung cancer	6.46e-05	0.000236	CcSEcCtD
Aprepitant—Vomiting—Gemcitabine—lung cancer	6.46e-05	0.000236	CcSEcCtD
Aprepitant—Bradycardia—Doxorubicin—lung cancer	6.45e-05	0.000235	CcSEcCtD
Aprepitant—Dyspnoea—Docetaxel—lung cancer	6.43e-05	0.000234	CcSEcCtD
Aprepitant—Somnolence—Docetaxel—lung cancer	6.41e-05	0.000234	CcSEcCtD
Aprepitant—Mental disorder—Methotrexate—lung cancer	6.41e-05	0.000234	CcSEcCtD
Aprepitant—Rash—Gemcitabine—lung cancer	6.41e-05	0.000234	CcSEcCtD
Aprepitant—Dermatitis—Gemcitabine—lung cancer	6.4e-05	0.000233	CcSEcCtD
Aprepitant—Hypersensitivity—Etoposide—lung cancer	6.39e-05	0.000233	CcSEcCtD
Aprepitant—Erythema—Methotrexate—lung cancer	6.37e-05	0.000232	CcSEcCtD
Aprepitant—Malnutrition—Methotrexate—lung cancer	6.37e-05	0.000232	CcSEcCtD
Aprepitant—Headache—Gemcitabine—lung cancer	6.36e-05	0.000232	CcSEcCtD
Aprepitant—Dyspepsia—Docetaxel—lung cancer	6.35e-05	0.000231	CcSEcCtD
Aprepitant—Hypoaesthesia—Doxorubicin—lung cancer	6.3e-05	0.00023	CcSEcCtD
Aprepitant—Pharyngitis—Doxorubicin—lung cancer	6.29e-05	0.000229	CcSEcCtD
Aprepitant—Decreased appetite—Docetaxel—lung cancer	6.27e-05	0.000229	CcSEcCtD
Aprepitant—Hypersensitivity—Paclitaxel—lung cancer	6.27e-05	0.000229	CcSEcCtD
Aprepitant—Urinary tract disorder—Doxorubicin—lung cancer	6.25e-05	0.000228	CcSEcCtD
Aprepitant—Dysgeusia—Methotrexate—lung cancer	6.23e-05	0.000227	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Docetaxel—lung cancer	6.22e-05	0.000227	CcSEcCtD
Aprepitant—Asthenia—Etoposide—lung cancer	6.22e-05	0.000227	CcSEcCtD
Aprepitant—Connective tissue disorder—Doxorubicin—lung cancer	6.22e-05	0.000227	CcSEcCtD
Aprepitant—Fatigue—Docetaxel—lung cancer	6.22e-05	0.000227	CcSEcCtD
Aprepitant—Urethral disorder—Doxorubicin—lung cancer	6.21e-05	0.000226	CcSEcCtD
Aprepitant—Nausea—Irinotecan—lung cancer	6.19e-05	0.000226	CcSEcCtD
Aprepitant—Constipation—Docetaxel—lung cancer	6.17e-05	0.000225	CcSEcCtD
Aprepitant—Pain—Docetaxel—lung cancer	6.17e-05	0.000225	CcSEcCtD
Aprepitant—Back pain—Methotrexate—lung cancer	6.16e-05	0.000225	CcSEcCtD
Aprepitant—Pruritus—Etoposide—lung cancer	6.14e-05	0.000224	CcSEcCtD
Aprepitant—Asthenia—Paclitaxel—lung cancer	6.1e-05	0.000223	CcSEcCtD
Aprepitant—Nausea—Gemcitabine—lung cancer	6.03e-05	0.00022	CcSEcCtD
Aprepitant—Vomiting—Cisplatin—lung cancer	6.02e-05	0.00022	CcSEcCtD
Aprepitant—Pruritus—Paclitaxel—lung cancer	6.02e-05	0.000219	CcSEcCtD
Aprepitant—Erythema multiforme—Doxorubicin—lung cancer	5.99e-05	0.000218	CcSEcCtD
Aprepitant—Rash—Cisplatin—lung cancer	5.97e-05	0.000218	CcSEcCtD
Aprepitant—Dermatitis—Cisplatin—lung cancer	5.97e-05	0.000218	CcSEcCtD
Aprepitant—Feeling abnormal—Docetaxel—lung cancer	5.94e-05	0.000217	CcSEcCtD
Aprepitant—Diarrhoea—Etoposide—lung cancer	5.94e-05	0.000216	CcSEcCtD
Aprepitant—Eye disorder—Doxorubicin—lung cancer	5.92e-05	0.000216	CcSEcCtD
Aprepitant—Ill-defined disorder—Methotrexate—lung cancer	5.91e-05	0.000215	CcSEcCtD
Aprepitant—Tinnitus—Doxorubicin—lung cancer	5.9e-05	0.000215	CcSEcCtD
Aprepitant—Gastrointestinal pain—Docetaxel—lung cancer	5.9e-05	0.000215	CcSEcCtD
Aprepitant—Anaemia—Methotrexate—lung cancer	5.88e-05	0.000215	CcSEcCtD
Aprepitant—Flushing—Doxorubicin—lung cancer	5.88e-05	0.000214	CcSEcCtD
Aprepitant—Cardiac disorder—Doxorubicin—lung cancer	5.88e-05	0.000214	CcSEcCtD
Aprepitant—Diarrhoea—Paclitaxel—lung cancer	5.82e-05	0.000212	CcSEcCtD
Aprepitant—Angiopathy—Doxorubicin—lung cancer	5.75e-05	0.00021	CcSEcCtD
Aprepitant—Malaise—Methotrexate—lung cancer	5.74e-05	0.000209	CcSEcCtD
Aprepitant—Dizziness—Etoposide—lung cancer	5.74e-05	0.000209	CcSEcCtD
Aprepitant—Immune system disorder—Doxorubicin—lung cancer	5.72e-05	0.000209	CcSEcCtD
Aprepitant—Mediastinal disorder—Doxorubicin—lung cancer	5.71e-05	0.000208	CcSEcCtD
Aprepitant—Abdominal pain—Docetaxel—lung cancer	5.7e-05	0.000208	CcSEcCtD
Aprepitant—Body temperature increased—Docetaxel—lung cancer	5.7e-05	0.000208	CcSEcCtD
Aprepitant—Chills—Doxorubicin—lung cancer	5.68e-05	0.000207	CcSEcCtD
Aprepitant—Dizziness—Paclitaxel—lung cancer	5.62e-05	0.000205	CcSEcCtD
Aprepitant—Nausea—Cisplatin—lung cancer	5.62e-05	0.000205	CcSEcCtD
Aprepitant—Alopecia—Doxorubicin—lung cancer	5.6e-05	0.000204	CcSEcCtD
Aprepitant—Cough—Methotrexate—lung cancer	5.56e-05	0.000203	CcSEcCtD
Aprepitant—Mental disorder—Doxorubicin—lung cancer	5.55e-05	0.000202	CcSEcCtD
Aprepitant—Convulsion—Methotrexate—lung cancer	5.52e-05	0.000201	CcSEcCtD
Aprepitant—Vomiting—Etoposide—lung cancer	5.52e-05	0.000201	CcSEcCtD
Aprepitant—Erythema—Doxorubicin—lung cancer	5.51e-05	0.000201	CcSEcCtD
Aprepitant—Malnutrition—Doxorubicin—lung cancer	5.51e-05	0.000201	CcSEcCtD
Aprepitant—Rash—Etoposide—lung cancer	5.47e-05	0.000199	CcSEcCtD
Aprepitant—Dermatitis—Etoposide—lung cancer	5.46e-05	0.000199	CcSEcCtD
Aprepitant—Headache—Etoposide—lung cancer	5.43e-05	0.000198	CcSEcCtD
Aprepitant—Flatulence—Doxorubicin—lung cancer	5.43e-05	0.000198	CcSEcCtD
Aprepitant—Chest pain—Methotrexate—lung cancer	5.42e-05	0.000198	CcSEcCtD
Aprepitant—Arthralgia—Methotrexate—lung cancer	5.42e-05	0.000198	CcSEcCtD
Aprepitant—Myalgia—Methotrexate—lung cancer	5.42e-05	0.000198	CcSEcCtD
Aprepitant—Vomiting—Paclitaxel—lung cancer	5.41e-05	0.000197	CcSEcCtD
Aprepitant—Dysgeusia—Doxorubicin—lung cancer	5.4e-05	0.000197	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	5.38e-05	0.000196	CcSEcCtD
Aprepitant—Rash—Paclitaxel—lung cancer	5.36e-05	0.000196	CcSEcCtD
Aprepitant—Dermatitis—Paclitaxel—lung cancer	5.36e-05	0.000195	CcSEcCtD
Aprepitant—Discomfort—Methotrexate—lung cancer	5.36e-05	0.000195	CcSEcCtD
Aprepitant—Back pain—Doxorubicin—lung cancer	5.33e-05	0.000194	CcSEcCtD
Aprepitant—Headache—Paclitaxel—lung cancer	5.33e-05	0.000194	CcSEcCtD
Aprepitant—Hypersensitivity—Docetaxel—lung cancer	5.31e-05	0.000194	CcSEcCtD
Aprepitant—Muscle spasms—Doxorubicin—lung cancer	5.3e-05	0.000193	CcSEcCtD
Aprepitant—Confusional state—Methotrexate—lung cancer	5.24e-05	0.000191	CcSEcCtD
Aprepitant—Anaphylactic shock—Methotrexate—lung cancer	5.2e-05	0.00019	CcSEcCtD
Aprepitant—Asthenia—Docetaxel—lung cancer	5.17e-05	0.000189	CcSEcCtD
Aprepitant—Infection—Methotrexate—lung cancer	5.16e-05	0.000188	CcSEcCtD
Aprepitant—Nausea—Etoposide—lung cancer	5.15e-05	0.000188	CcSEcCtD
Aprepitant—Ill-defined disorder—Doxorubicin—lung cancer	5.12e-05	0.000187	CcSEcCtD
Aprepitant—Pruritus—Docetaxel—lung cancer	5.1e-05	0.000186	CcSEcCtD
Aprepitant—Nervous system disorder—Methotrexate—lung cancer	5.1e-05	0.000186	CcSEcCtD
Aprepitant—Anaemia—Doxorubicin—lung cancer	5.1e-05	0.000186	CcSEcCtD
Aprepitant—Thrombocytopenia—Methotrexate—lung cancer	5.09e-05	0.000186	CcSEcCtD
Aprepitant—Nausea—Paclitaxel—lung cancer	5.05e-05	0.000184	CcSEcCtD
Aprepitant—Skin disorder—Methotrexate—lung cancer	5.05e-05	0.000184	CcSEcCtD
Aprepitant—Hyperhidrosis—Methotrexate—lung cancer	5.02e-05	0.000183	CcSEcCtD
Aprepitant—Malaise—Doxorubicin—lung cancer	4.97e-05	0.000181	CcSEcCtD
Aprepitant—Anorexia—Methotrexate—lung cancer	4.95e-05	0.000181	CcSEcCtD
Aprepitant—Syncope—Doxorubicin—lung cancer	4.94e-05	0.00018	CcSEcCtD
Aprepitant—Diarrhoea—Docetaxel—lung cancer	4.93e-05	0.00018	CcSEcCtD
Aprepitant—Palpitations—Doxorubicin—lung cancer	4.87e-05	0.000178	CcSEcCtD
Aprepitant—Hypotension—Methotrexate—lung cancer	4.86e-05	0.000177	CcSEcCtD
Aprepitant—Loss of consciousness—Doxorubicin—lung cancer	4.85e-05	0.000177	CcSEcCtD
Aprepitant—Cough—Doxorubicin—lung cancer	4.81e-05	0.000175	CcSEcCtD
Aprepitant—Convulsion—Doxorubicin—lung cancer	4.78e-05	0.000174	CcSEcCtD
Aprepitant—Dizziness—Docetaxel—lung cancer	4.77e-05	0.000174	CcSEcCtD
Aprepitant—Hypertension—Doxorubicin—lung cancer	4.76e-05	0.000174	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Methotrexate—lung cancer	4.73e-05	0.000173	CcSEcCtD
Aprepitant—Insomnia—Methotrexate—lung cancer	4.7e-05	0.000171	CcSEcCtD
Aprepitant—Arthralgia—Doxorubicin—lung cancer	4.69e-05	0.000171	CcSEcCtD
Aprepitant—Chest pain—Doxorubicin—lung cancer	4.69e-05	0.000171	CcSEcCtD
Aprepitant—Myalgia—Doxorubicin—lung cancer	4.69e-05	0.000171	CcSEcCtD
Aprepitant—Anxiety—Doxorubicin—lung cancer	4.68e-05	0.000171	CcSEcCtD
Aprepitant—Paraesthesia—Methotrexate—lung cancer	4.67e-05	0.00017	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	4.66e-05	0.00017	CcSEcCtD
Aprepitant—Discomfort—Doxorubicin—lung cancer	4.64e-05	0.000169	CcSEcCtD
Aprepitant—Dyspnoea—Methotrexate—lung cancer	4.63e-05	0.000169	CcSEcCtD
Aprepitant—Somnolence—Methotrexate—lung cancer	4.62e-05	0.000168	CcSEcCtD
Aprepitant—Dry mouth—Doxorubicin—lung cancer	4.59e-05	0.000167	CcSEcCtD
Aprepitant—Vomiting—Docetaxel—lung cancer	4.58e-05	0.000167	CcSEcCtD
Aprepitant—Dyspepsia—Methotrexate—lung cancer	4.57e-05	0.000167	CcSEcCtD
Aprepitant—Rash—Docetaxel—lung cancer	4.55e-05	0.000166	CcSEcCtD
Aprepitant—Dermatitis—Docetaxel—lung cancer	4.54e-05	0.000166	CcSEcCtD
Aprepitant—Confusional state—Doxorubicin—lung cancer	4.54e-05	0.000165	CcSEcCtD
Aprepitant—Decreased appetite—Methotrexate—lung cancer	4.52e-05	0.000165	CcSEcCtD
Aprepitant—Headache—Docetaxel—lung cancer	4.52e-05	0.000165	CcSEcCtD
Aprepitant—Anaphylactic shock—Doxorubicin—lung cancer	4.5e-05	0.000164	CcSEcCtD
Aprepitant—Oedema—Doxorubicin—lung cancer	4.5e-05	0.000164	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Methotrexate—lung cancer	4.49e-05	0.000164	CcSEcCtD
Aprepitant—Fatigue—Methotrexate—lung cancer	4.48e-05	0.000163	CcSEcCtD
Aprepitant—Infection—Doxorubicin—lung cancer	4.47e-05	0.000163	CcSEcCtD
Aprepitant—Pain—Methotrexate—lung cancer	4.44e-05	0.000162	CcSEcCtD
Aprepitant—Shock—Doxorubicin—lung cancer	4.43e-05	0.000161	CcSEcCtD
Aprepitant—Nervous system disorder—Doxorubicin—lung cancer	4.41e-05	0.000161	CcSEcCtD
Aprepitant—Thrombocytopenia—Doxorubicin—lung cancer	4.41e-05	0.000161	CcSEcCtD
Aprepitant—Tachycardia—Doxorubicin—lung cancer	4.39e-05	0.00016	CcSEcCtD
Aprepitant—Skin disorder—Doxorubicin—lung cancer	4.37e-05	0.000159	CcSEcCtD
Aprepitant—Hyperhidrosis—Doxorubicin—lung cancer	4.35e-05	0.000159	CcSEcCtD
Aprepitant—Anorexia—Doxorubicin—lung cancer	4.29e-05	0.000156	CcSEcCtD
Aprepitant—Nausea—Docetaxel—lung cancer	4.28e-05	0.000156	CcSEcCtD
Aprepitant—Feeling abnormal—Methotrexate—lung cancer	4.28e-05	0.000156	CcSEcCtD
Aprepitant—Gastrointestinal pain—Methotrexate—lung cancer	4.25e-05	0.000155	CcSEcCtD
Aprepitant—Hypotension—Doxorubicin—lung cancer	4.2e-05	0.000153	CcSEcCtD
Aprepitant—Urticaria—Methotrexate—lung cancer	4.13e-05	0.000151	CcSEcCtD
Aprepitant—Abdominal pain—Methotrexate—lung cancer	4.11e-05	0.00015	CcSEcCtD
Aprepitant—Body temperature increased—Methotrexate—lung cancer	4.11e-05	0.00015	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Doxorubicin—lung cancer	4.1e-05	0.00015	CcSEcCtD
Aprepitant—Insomnia—Doxorubicin—lung cancer	4.07e-05	0.000148	CcSEcCtD
Aprepitant—Paraesthesia—Doxorubicin—lung cancer	4.04e-05	0.000147	CcSEcCtD
Aprepitant—Dyspnoea—Doxorubicin—lung cancer	4.01e-05	0.000146	CcSEcCtD
Aprepitant—Somnolence—Doxorubicin—lung cancer	4e-05	0.000146	CcSEcCtD
Aprepitant—Dyspepsia—Doxorubicin—lung cancer	3.96e-05	0.000144	CcSEcCtD
Aprepitant—Decreased appetite—Doxorubicin—lung cancer	3.91e-05	0.000143	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Doxorubicin—lung cancer	3.88e-05	0.000142	CcSEcCtD
Aprepitant—Fatigue—Doxorubicin—lung cancer	3.88e-05	0.000141	CcSEcCtD
Aprepitant—Constipation—Doxorubicin—lung cancer	3.85e-05	0.00014	CcSEcCtD
Aprepitant—Pain—Doxorubicin—lung cancer	3.85e-05	0.00014	CcSEcCtD
Aprepitant—Hypersensitivity—Methotrexate—lung cancer	3.83e-05	0.00014	CcSEcCtD
Aprepitant—Asthenia—Methotrexate—lung cancer	3.73e-05	0.000136	CcSEcCtD
Aprepitant—Feeling abnormal—Doxorubicin—lung cancer	3.71e-05	0.000135	CcSEcCtD
Aprepitant—Gastrointestinal pain—Doxorubicin—lung cancer	3.68e-05	0.000134	CcSEcCtD
Aprepitant—Pruritus—Methotrexate—lung cancer	3.68e-05	0.000134	CcSEcCtD
Aprepitant—Urticaria—Doxorubicin—lung cancer	3.57e-05	0.00013	CcSEcCtD
Aprepitant—Abdominal pain—Doxorubicin—lung cancer	3.56e-05	0.00013	CcSEcCtD
Aprepitant—Body temperature increased—Doxorubicin—lung cancer	3.56e-05	0.00013	CcSEcCtD
Aprepitant—Diarrhoea—Methotrexate—lung cancer	3.56e-05	0.00013	CcSEcCtD
Aprepitant—Dizziness—Methotrexate—lung cancer	3.44e-05	0.000125	CcSEcCtD
Aprepitant—Hypersensitivity—Doxorubicin—lung cancer	3.32e-05	0.000121	CcSEcCtD
Aprepitant—Vomiting—Methotrexate—lung cancer	3.3e-05	0.00012	CcSEcCtD
Aprepitant—Rash—Methotrexate—lung cancer	3.28e-05	0.000119	CcSEcCtD
Aprepitant—Dermatitis—Methotrexate—lung cancer	3.27e-05	0.000119	CcSEcCtD
Aprepitant—Headache—Methotrexate—lung cancer	3.26e-05	0.000119	CcSEcCtD
Aprepitant—Asthenia—Doxorubicin—lung cancer	3.23e-05	0.000118	CcSEcCtD
Aprepitant—Pruritus—Doxorubicin—lung cancer	3.18e-05	0.000116	CcSEcCtD
Aprepitant—Nausea—Methotrexate—lung cancer	3.09e-05	0.000113	CcSEcCtD
Aprepitant—Diarrhoea—Doxorubicin—lung cancer	3.08e-05	0.000112	CcSEcCtD
Aprepitant—Dizziness—Doxorubicin—lung cancer	2.98e-05	0.000109	CcSEcCtD
Aprepitant—Vomiting—Doxorubicin—lung cancer	2.86e-05	0.000104	CcSEcCtD
Aprepitant—Rash—Doxorubicin—lung cancer	2.84e-05	0.000103	CcSEcCtD
Aprepitant—Dermatitis—Doxorubicin—lung cancer	2.83e-05	0.000103	CcSEcCtD
Aprepitant—Headache—Doxorubicin—lung cancer	2.82e-05	0.000103	CcSEcCtD
Aprepitant—Nausea—Doxorubicin—lung cancer	2.67e-05	9.75e-05	CcSEcCtD
Aprepitant—CYP3A4—Metabolism—CKB—lung cancer	1.26e-05	0.000103	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTA1—lung cancer	1.25e-05	0.000102	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—RRM1—lung cancer	1.24e-05	0.000102	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTA3—lung cancer	1.24e-05	0.000102	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—VEGFA—lung cancer	1.24e-05	0.000101	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ABCC3—lung cancer	1.24e-05	0.000101	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ABCB1—lung cancer	1.23e-05	0.000101	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GNG11—lung cancer	1.23e-05	0.000101	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—STAT3—lung cancer	1.23e-05	0.0001	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—NRAS—lung cancer	1.22e-05	0.0001	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—APOA1—lung cancer	1.22e-05	0.0001	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TYMS—lung cancer	1.21e-05	9.91e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTM1—lung cancer	1.2e-05	9.8e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKR1C1—lung cancer	1.2e-05	9.79e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CNDP2—lung cancer	1.19e-05	9.73e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTM2—lung cancer	1.19e-05	9.73e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MAPK3—lung cancer	1.17e-05	9.59e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALDOA—lung cancer	1.17e-05	9.57e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—B4GALT5—lung cancer	1.17e-05	9.55e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—UGT1A1—lung cancer	1.16e-05	9.51e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—MTMR3—lung cancer	1.16e-05	9.46e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP2E1—lung cancer	1.14e-05	9.35e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MYC—lung cancer	1.14e-05	9.33e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTA4—lung cancer	1.14e-05	9.29e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NCOA3—lung cancer	1.14e-05	9.29e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP1A1—lung cancer	1.14e-05	9.29e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NQO1—lung cancer	1.13e-05	9.24e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PGAM1—lung cancer	1.13e-05	9.22e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ERCC2—lung cancer	1.13e-05	9.21e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GNG11—lung cancer	1.12e-05	9.17e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.12e-05	9.13e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EGFR—lung cancer	1.12e-05	9.12e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—lung cancer	1.11e-05	9.12e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—lung cancer	1.11e-05	9.08e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTA2—lung cancer	1.11e-05	9.06e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ABCG2—lung cancer	1.1e-05	9.04e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ADCY1—lung cancer	1.1e-05	9.04e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ENO2—lung cancer	1.08e-05	8.86e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—HPGDS—lung cancer	1.08e-05	8.86e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PPP2R1B—lung cancer	1.08e-05	8.81e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP2A7—lung cancer	1.08e-05	8.8e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTA1—lung cancer	1.07e-05	8.74e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALDOA—lung cancer	1.07e-05	8.73e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.06e-05	8.69e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ABCC3—lung cancer	1.06e-05	8.64e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KRAS—lung cancer	1.05e-05	8.62e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SDC4—lung cancer	1.05e-05	8.61e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTT1—lung cancer	1.05e-05	8.6e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP2A6—lung cancer	1.04e-05	8.5e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GCLC—lung cancer	1.04e-05	8.5e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NCOA3—lung cancer	1.04e-05	8.47e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.03e-05	8.47e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKR1C1—lung cancer	1.02e-05	8.37e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—STK11—lung cancer	1.02e-05	8.33e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.02e-05	8.33e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ADCY1—lung cancer	1.01e-05	8.24e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ABCG2—lung cancer	1.01e-05	8.24e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—UGT1A1—lung cancer	9.93e-06	8.12e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ENO2—lung cancer	9.88e-06	8.08e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—HPGDS—lung cancer	9.88e-06	8.08e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ENO1—lung cancer	9.85e-06	8.06e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PPP2R1B—lung cancer	9.82e-06	8.03e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	9.81e-06	8.03e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—APOA1—lung cancer	9.74e-06	7.97e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	9.69e-06	7.92e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—ALB—lung cancer	9.69e-06	7.92e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PIK3CA—lung cancer	9.68e-06	7.92e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—RRM1—lung cancer	9.59e-06	7.84e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTA3—lung cancer	9.59e-06	7.84e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTT1—lung cancer	9.58e-06	7.84e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GNG11—lung cancer	9.57e-06	7.83e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—lung cancer	9.53e-06	7.79e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GCLC—lung cancer	9.47e-06	7.75e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP2A6—lung cancer	9.47e-06	7.75e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	9.44e-06	7.72e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTP1—lung cancer	9.42e-06	7.71e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—lung cancer	9.36e-06	7.66e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CAT—lung cancer	9.17e-06	7.5e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALDOA—lung cancer	9.12e-06	7.46e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—B4GALT5—lung cancer	9.01e-06	7.37e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ENO1—lung cancer	8.98e-06	7.35e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—HRAS—lung cancer	8.95e-06	7.32e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	8.95e-06	7.32e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ABCB1—lung cancer	8.92e-06	7.3e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CG—lung cancer	8.89e-06	7.28e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NCOA3—lung cancer	8.85e-06	7.24e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP2E1—lung cancer	8.83e-06	7.23e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	8.83e-06	7.22e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTA4—lung cancer	8.77e-06	7.17e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TYMS—lung cancer	8.76e-06	7.17e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NQO1—lung cancer	8.73e-06	7.14e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	8.7e-06	7.11e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTM1—lung cancer	8.66e-06	7.08e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ADCY1—lung cancer	8.61e-06	7.04e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ABCG2—lung cancer	8.61e-06	7.04e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL6—lung cancer	8.57e-06	7.01e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	8.55e-06	7e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTA2—lung cancer	8.54e-06	6.99e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	8.47e-06	6.93e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—POMC—lung cancer	8.47e-06	6.93e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—HPGDS—lung cancer	8.44e-06	6.91e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ENO2—lung cancer	8.44e-06	6.91e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PPP2R1B—lung cancer	8.39e-06	6.86e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—POMC—lung cancer	8.28e-06	6.77e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CREBBP—lung cancer	8.25e-06	6.75e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTA1—lung cancer	8.24e-06	6.74e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP1A1—lung cancer	8.21e-06	6.71e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTT1—lung cancer	8.19e-06	6.7e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ABCC3—lung cancer	8.15e-06	6.67e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ERCC2—lung cancer	8.14e-06	6.66e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GCLC—lung cancer	8.09e-06	6.62e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP2A6—lung cancer	8.09e-06	6.62e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	8.06e-06	6.6e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP2E1—lung cancer	8.05e-06	6.59e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NQO1—lung cancer	7.96e-06	6.51e-05	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AKT1—lung cancer	7.91e-06	6.47e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKR1C1—lung cancer	7.89e-06	6.46e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—STK11—lung cancer	7.87e-06	6.44e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CD—lung cancer	7.82e-06	6.4e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	7.8e-06	6.38e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	7.73e-06	6.32e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ALB—lung cancer	7.72e-06	6.31e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ENO1—lung cancer	7.67e-06	6.28e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—UGT1A1—lung cancer	7.66e-06	6.27e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	7.65e-06	6.25e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—ALB—lung cancer	7.55e-06	6.17e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	7.39e-06	6.05e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GNG11—lung cancer	7.39e-06	6.04e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTP1—lung cancer	7.28e-06	5.96e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—STK11—lung cancer	7.18e-06	5.87e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CAT—lung cancer	7.09e-06	5.8e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	7.05e-06	5.77e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—APOA1—lung cancer	7.04e-06	5.76e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALDOA—lung cancer	7.04e-06	5.76e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ABCB1—lung cancer	6.9e-06	5.64e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP2E1—lung cancer	6.88e-06	5.63e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NCOA3—lung cancer	6.83e-06	5.59e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CB—lung cancer	6.82e-06	5.58e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NQO1—lung cancer	6.81e-06	5.57e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TYMS—lung cancer	6.77e-06	5.54e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS2—lung cancer	6.75e-06	5.52e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	6.74e-06	5.51e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTM1—lung cancer	6.69e-06	5.48e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	6.66e-06	5.45e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ADCY1—lung cancer	6.64e-06	5.44e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ABCG2—lung cancer	6.64e-06	5.44e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTP1—lung cancer	6.64e-06	5.43e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	6.6e-06	5.4e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—HPGDS—lung cancer	6.52e-06	5.33e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ENO2—lung cancer	6.52e-06	5.33e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PPP2R1B—lung cancer	6.48e-06	5.3e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CAT—lung cancer	6.46e-06	5.29e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CG—lung cancer	6.43e-06	5.26e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	6.43e-06	5.26e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP1A1—lung cancer	6.35e-06	5.19e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTT1—lung cancer	6.32e-06	5.17e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ERCC2—lung cancer	6.29e-06	5.15e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ABCB1—lung cancer	6.29e-06	5.14e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP2A6—lung cancer	6.25e-06	5.11e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GCLC—lung cancer	6.25e-06	5.11e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TYMS—lung cancer	6.18e-06	5.05e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—STK11—lung cancer	6.13e-06	5.02e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—POMC—lung cancer	6.12e-06	5.01e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTM1—lung cancer	6.1e-06	4.99e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CREBBP—lung cancer	5.96e-06	4.88e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ENO1—lung cancer	5.92e-06	4.84e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTEN—lung cancer	5.89e-06	4.82e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP1A1—lung cancer	5.79e-06	4.73e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	5.76e-06	4.71e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ERCC2—lung cancer	5.74e-06	4.69e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTP1—lung cancer	5.68e-06	4.64e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CD—lung cancer	5.65e-06	4.62e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—EP300—lung cancer	5.62e-06	4.59e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ALB—lung cancer	5.58e-06	4.56e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CAT—lung cancer	5.52e-06	4.52e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—EP300—lung cancer	5.49e-06	4.49e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—APOA1—lung cancer	5.44e-06	4.45e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ABCB1—lung cancer	5.37e-06	4.4e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP2E1—lung cancer	5.31e-06	4.35e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TYMS—lung cancer	5.28e-06	4.32e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NQO1—lung cancer	5.25e-06	4.3e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTM1—lung cancer	5.22e-06	4.27e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.21e-06	4.26e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CG—lung cancer	4.97e-06	4.07e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—APOA1—lung cancer	4.96e-06	4.06e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP1A1—lung cancer	4.94e-06	4.04e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CB—lung cancer	4.93e-06	4.03e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ERCC2—lung cancer	4.9e-06	4.01e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS2—lung cancer	4.88e-06	3.99e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.75e-06	3.89e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—STK11—lung cancer	4.73e-06	3.87e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—POMC—lung cancer	4.73e-06	3.87e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CREBBP—lung cancer	4.61e-06	3.77e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CG—lung cancer	4.53e-06	3.71e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTP1—lung cancer	4.38e-06	3.58e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CD—lung cancer	4.37e-06	3.57e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—POMC—lung cancer	4.31e-06	3.53e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ALB—lung cancer	4.31e-06	3.53e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CAT—lung cancer	4.26e-06	3.49e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTEN—lung cancer	4.26e-06	3.48e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—APOA1—lung cancer	4.24e-06	3.47e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CREBBP—lung cancer	4.2e-06	3.44e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PIK3CA—lung cancer	4.15e-06	3.4e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ABCB1—lung cancer	4.15e-06	3.39e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TYMS—lung cancer	4.07e-06	3.33e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.06e-06	3.32e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—EP300—lung cancer	4.06e-06	3.32e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTM1—lung cancer	4.03e-06	3.29e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CD—lung cancer	3.98e-06	3.26e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ALB—lung cancer	3.93e-06	3.22e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CG—lung cancer	3.87e-06	3.17e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CYP1A1—lung cancer	3.82e-06	3.12e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CB—lung cancer	3.81e-06	3.12e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ERCC2—lung cancer	3.78e-06	3.1e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS2—lung cancer	3.77e-06	3.09e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—POMC—lung cancer	3.69e-06	3.02e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CREBBP—lung cancer	3.59e-06	2.94e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CB—lung cancer	3.47e-06	2.84e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS2—lung cancer	3.44e-06	2.81e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CD—lung cancer	3.4e-06	2.79e-05	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AKT1—lung cancer	3.39e-06	2.78e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ALB—lung cancer	3.36e-06	2.75e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTEN—lung cancer	3.29e-06	2.69e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—APOA1—lung cancer	3.27e-06	2.68e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—EP300—lung cancer	3.14e-06	2.57e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PIK3CA—lung cancer	3e-06	2.46e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTEN—lung cancer	3e-06	2.45e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CG—lung cancer	2.99e-06	2.45e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CB—lung cancer	2.97e-06	2.43e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS2—lung cancer	2.94e-06	2.41e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—EP300—lung cancer	2.86e-06	2.34e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—POMC—lung cancer	2.85e-06	2.33e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CREBBP—lung cancer	2.77e-06	2.27e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CD—lung cancer	2.63e-06	2.15e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ALB—lung cancer	2.59e-06	2.12e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTEN—lung cancer	2.56e-06	2.1e-05	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AKT1—lung cancer	2.45e-06	2.01e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—EP300—lung cancer	2.45e-06	2e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PIK3CA—lung cancer	2.32e-06	1.9e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CB—lung cancer	2.29e-06	1.87e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS2—lung cancer	2.27e-06	1.86e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PIK3CA—lung cancer	2.12e-06	1.73e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTEN—lung cancer	1.98e-06	1.62e-05	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AKT1—lung cancer	1.9e-06	1.55e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—EP300—lung cancer	1.89e-06	1.54e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PIK3CA—lung cancer	1.81e-06	1.48e-05	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AKT1—lung cancer	1.73e-06	1.41e-05	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AKT1—lung cancer	1.48e-06	1.21e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PIK3CA—lung cancer	1.4e-06	1.14e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AKT1—lung cancer	1.14e-06	9.33e-06	CbGpPWpGaD
